Pyxis Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pyxis Oncology (PYXS).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$9Upside to Avg. PT+380.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$6→$8
Sep 10, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$7→$8
Sep 9, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$12→$19
Aug 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$7
Aug 3, 2026	Wells Fargo	Derek Archila	Initiate	Overweight	$12
Jul 2, 2026	Leerink Partners	Jeffrey La Rosa	PT Cut	Outperform	$9→$7
May 5, 2026	Wedbush	Robert Driscoll	Initiate	Outperform	$6
Mar 24, 2026	Stifel	Bradley Canino	PT Cut	Buy	$9→$8
Mar 24, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$7
Dec 19, 2025	RBC Capital	Leonid Timashev	PT Cut	Outperform	$8→$5
Dec 19, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$5→$7
Nov 24, 2025	Stephens & Co.	Sudan Loganathan	PT Raise	Overweight	$5→$8
Nov 4, 2025	Guggenheim	Brad Canino	PT Raise	Buy	$5→$7
Sep 4, 2025	Guggenheim	Brad Canino	Initiate	Buy	$5
Aug 19, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$5
May 19, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$5
Mar 19, 2025	RBC Capital	Leonid Timashev	Maintained	Outperform	$8
Mar 19, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$5
Dec 20, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$7→$5
Dec 20, 2024	RBC Capital	Leonid Timashev	PT Cut	Outperform	$10→$8

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.

Benzinga Newsdesk

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.

Vandana Singh

PRO
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

Wells Fargo analyst Derek Archila maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $12 to $19.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.

Benzinga Newsdesk

This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. Analysts have mixed opinions on SCHW stock.

Avi Kapoor

Pyxis Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Pyxis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

PRO
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

PRO
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

PRO
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

People Also Watch

People Also Watch

Pyxis Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Pyxis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

PROHC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

PROWells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

PROHC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

PRO
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

PRO
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target